News

Biogasol attracts €15m
Enlarge image

FundingDenmarkCyprus

Biogasol attracts €15m

13.11.2012 - Danish Biogasol receives €15m equity and state money to test an lignocellulosic ethanol-production technology in a large-scale setting.

The renewable energy company BioGasol ApS from Ballerup has raised €15m. One third of the sum is new equity financing consisting of a co-investment by the current majority shareholder, Cyprus-based Fjord Capital Partners Ltd, and Unipension, a leading Danish pension fund managing assets of more than €12bn. €10m stems from a grant which has been approved by the Energy Technology Development and Demonstration Program (EUDP), a part of the Danish Energy Agency. BioGasol owns an appreciated, innovative pre-treatment reactor design for the cost-efficient and highly controlled conversion of lignocellulosic biomass into replacements for conventional fuels and other oil-based materials. The money is supposed to be used for transfering BioGasol's proprietary technology into demonstration scale. The large-scale testing plant will be built in Denmark starting in Q1/2013. "Our new demonstration facility will be co-financed by our industrial partners, SweetWater Energy in the US and a Scandinavian strategic partner," stated BioGasol's CEO Anders Weber.

Biogasol ApS is a Danish biotechnology company. Since its inception in 2006 as a spinout from the Technical University of Denmark, it already has successfully developed a pentose/hexose co-fermentation technology on pilot scale that makes use of metabolically engineered thermophilic bacteria. Biogasol develops so-called 2nd generation bioethanol by focussing on agricultural waste and wood as a source of lignocellulose.

Italian pioneer Chemtex group on the other hand is about to open a US bioethanol plant which will use non-food grasses grown on marginal land. Interestingly, Chemtex relies on the biomass processing enzymes produced by another Danish company, Novozymes. Biogasol is also uses some Novozymes enzymes. However, the company also owns proprietary and patented organisms like a heat-loving thermophilic bacterium isolated 20 years ago from a thermal spring in Iceland or a xylose-converting bacterium.

© eurobiotechnews.eu/ml

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3022.0%
  • GW PHARMACEUTICALS (UK)426.00 GBP654.0%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.28 CHF-91.8%
  • THROMBOGENICS (B)9.14 EUR-70.6%

No liability assumed, Date: 29.07.2014